Biologic Agents and Secondary Immune Deficiency

Heather Axelrod; Matthew Adams

doi:10.1016/j.iac.2021.07.006

Biologic Agents and Secondary Immune Deficiency

Immunol Allergy Clin North Am. 2021 Nov;41(4):639-652. doi: 10.1016/j.iac.2021.07.006.

Authors

Heather Axelrod¹, Matthew Adams²

Affiliations

¹ Department of Pediatrics (PGY3), Children's Hospital of Michigan, Detroit, MI, USA.
² Division of Pediatric Rheumatology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University, 3950 Beaubien Boulevard, Detroit, MI 48201, USA. Electronic address: madams3@dmc.org.

PMID: 34602234
DOI: 10.1016/j.iac.2021.07.006

Abstract

Biologics are protein-based pharmaceuticals derived from living organisms or their proteins. We discuss the mechanism of action for currently approved biologics and a give summary of the studies on immune suppression from biologics. Most of these studies have been conducted with rheumatology patients, and many in adults. Their relevance for children is explored and existing gaps in data for children are highlighted.

Keywords: Anti-inflammatory; Biologics; Immunosuppression; Monoclonal antibodies; Secondary immune deficiency; TNF-α inhibitors.

Publication types

Review

MeSH terms

Adult
Biological Factors*
Biological Products* / therapeutic use
Child
Humans

Substances

Biological Factors
Biological Products